Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erbium (169Er) citrate colloid
- Development stage
- Unknown
- Lead developer
- CISBIO
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intraarticular
01
Overview
erbium (169Er) citrate colloid (ERMM-1) is a therapeutic radiopharmaceutical containing the beta-emitting radionuclide erbium-169, developed by CIS bio international (now part of Curium). It is indicated for the treatment of rheumatoid mono- or oligo-arthritis affecting the small joints of the hands and feet (radiation synovectomy/synoviorthesis) following the failure of intra-articular corticosteroid therapy. Administered via local intra-articular injection, the colloidal particles are phagocytised by synovial cells, delivering localized beta radiation with a maximum tissue range of approximately 1.0 mm. This targeted radiation induces coagulation necrosis of the inflamed synovial membrane, leading to the resolution of joint inflammation while minimizing radiation exposure to surrounding healthy tissues.
- Brand names
- Ermm-1Ermm1Ermm 1
- Other names
- erbium (169Er) citrateerbium (169Er) citrate colloiderbium citrate colloid (169Er)erbium-169 citrateerbium169 citrateerbium 169 citrateerbium-169 citrate colloiderbium169 citrate colloiderbium 169 citrate colloid
Beyond the preview
Go deeper on erbium (169Er) citrate colloid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erbium (169Er) citrate colloid.